{"name":"Assertio Holdings","slug":"assertio","ticker":"ASRT","exchange":"NASDAQ","domain":"assertiotx.com","description":"Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Asse","hq":"Lake Forest, IL","founded":0,"employees":"53","ceo":"Todd N. Smith (Interim)","sector":"Specialty Pharma — Pain & Neurology","stockPrice":23.32,"stockChange":0,"stockChangePercent":0,"marketCap":"$151M","metrics":{"revenue":118713000,"revenueGrowth":-57.9,"grossMargin":70.2,"rdSpend":1690000,"netIncome":-30375000,"cash":63405000,"dividendYield":0,"peRatio":9,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2025-06-01","label":"Toviaz patent cliff ($143.8M at risk)","drug":"Toviaz","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2022-02-24","type":"earnings","headline":"Assertio Holdings Reports Fourth Quarter and Full Year 2021 Financial Results","summary":"Assertio Holdings reported fourth quarter and full year 2021 financial results, with revenue of $143.8 million and a net loss of $11.4 million.","drugName":"","sentiment":"neutral"},{"date":"2021-05-14","type":"deal","headline":"Assertio Holdings Announces Sale of Toviaz to Mallinckrodt Pharmaceuticals","summary":"Assertio Holdings announced the sale of Toviaz to Mallinckrodt Pharmaceuticals for $360 million.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-27","type":"earnings","source":"simplywall.st","summary":"Assessing Assertio Holdings (ASRT) Valuation After 2025 Earnings Results And 2026 Sales Guidance - simplywall.st","headline":"Assessing Assertio Holdings (ASRT) Valuation After 2025 Earnings Results And 2026 Sales Guidance","sentiment":"neutral"},{"date":"2026-03-16","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-07","type":"pipeline","source":"simplywall.st","summary":"Assertio Holdings, Inc.'s (NASDAQ:ASRT) Shares Bounce 35% But Its Business Still Trails The Industry - simplywall.st","headline":"Assertio Holdings, Inc.'s (NASDAQ:ASRT) Shares Bounce 35% But Its Business Still Trails The Industry","sentiment":"neutral"},{"date":"2026-01-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-12-22","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-05","type":"pipeline","source":"simplywall.st","summary":"Assertio Holdings (NASDAQ:ASRT shareholders incur further losses as stock declines 11% this week, taking three-year losses to 72% - simplywall.st","headline":"Assertio Holdings (NASDAQ:ASRT shareholders incur further losses as stock declines 11% this week, taking three-year loss","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAJBVV95cUxQcTE0TS0tT3lJUVQ1MEdMeVQ5TmRzbnlWMTZ6RjZqWGo1a0xMeHZuN2xBZTV5anpnNkUwaHFDbm1kYXl1R21VaGFocHptZXZ3UURzamVSQVdXNS1hc1JKQXFsTFc4NHZDZ1RrY2JGZE50ckN5bjVqQ0ZPSzdpQ29NcmNINnhJRlFXcEtJOEQ5Smg5SGhNajBXekV5SHJRQkVhWkRNbDZ5Q2h2SUFzOEd2UlpNeDVCd0MzZjd1N2FkeDdBLU9iM0Z4ZWkwRk45UWFueW1OZjFSTlJCOXlvOGFFdmdWZDgxSklEUHRpdmNJeXh6X1lDRm80VlZORGd4LU4xbk96M3JMcUVXV2N6NmRmcTZ1WDE1QTdkR3RWbWpaZzctY3Zy?oc=5","date":"2025-09-19","type":"pipeline","source":"globenewswire.com","summary":"Spectrum Pharmaceuticals (SPPI) and Assertio Holdings - globenewswire.com","headline":"Spectrum Pharmaceuticals (SPPI) and Assertio Holdings","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBFUDBlUkRUdEpXeHR3TzFLVTN2YnhoQnZvS21LTjc5djRXR1lvcjE3dm1LallDb1pwdGN0cTIweEh0UW50THhxVHpuWWd1aGk0a0Rj?oc=5","date":"2025-04-24","type":"pipeline","source":"Stock Titan","summary":"ASRT Stock Price, News & Analysis | Assertio Holdings - Stock Titan","headline":"ASRT Stock Price, News & Analysis | Assertio Holdings","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPVmZZX0I5ZW41V01yci1sZE5qZXpsLUFDSDlYeWlkYjkyckg1ejROMkxmUS1UUFZza3llS2g2MU9KMHNhSnJyN1M2YnZiTkM2WDQ4WGZ3SngxWVE3WVUxU0RrQmRtLUY4N3FsdW4yemhqT296UHFobUlkS3FNU0lBOHA1cElsVks1d0x1cnZIVHBQMjhOOWZ6RFVTdjdZUFBLTTFhLVprb0JpUnFwYngyakRnNUtOeGJSU2c?oc=5","date":"2025-01-29","type":"pipeline","source":"Investing.com","summary":"Assertio Holdings faces Nasdaq delisting over share price rule - Investing.com","headline":"Assertio Holdings faces Nasdaq delisting over share price rule","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPWU9lZDVTaHhPaThBUnNVQ3JnU293RXd3T3BnNVpsQlNGQ0U3MGgyT3dyNXNDQlZzOFdKcVdLa0hOanlSQWVVaHY0UC1yNmtrUE9xd2xLLW5tYTM1UU9KMDJCYkdieGNETDVhb2FrdDI0bTdBZDdQVi1MZjZZUzZKMExJUDRkbUhpU3l2VjFnYnYzZlM5OHFNTTR2aGp5Tl9LRzhaem1jZGRmalRqdTdmTEpEakt0QXVwcVVkSmRB?oc=5","date":"2024-12-12","type":"pipeline","source":"Stock Titan","summary":"Assertio Holdings Creates Transformation Office, Appoints New Leadership to Drive Growth Strategy - Stock Titan","headline":"Assertio Holdings Creates Transformation Office, Appoints New Leadership to Drive Growth Strategy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxNc3doTDBCLVdkbEYwd1pfM3FPTFZLaC1PLWNQRURpQkpSdDg0MllyTktTQ25FWjdWY1FCbTdkcW1ibFJweDk3LXRQWlVEcjdRdENJRnNNcnlwZ3RwMV9TbHVFQmZydU1Xak1ZdlUwVHJXYm5RNWpMU3dSLTdaTS1pblBaSllYb21VT1N6N1ZKRTZhRWY5VG9xb2pfYzBVdm1EMHRMX3ZTNnNRZXM?oc=5","date":"2024-09-11","type":"pipeline","source":"Seeking Alpha","summary":"Assertio Holdings: Management Change Could Improve Comeback Chances (NASDAQ:ASRT) - Seeking Alpha","headline":"Assertio Holdings: Management Change Could Improve Comeback Chances (NASDAQ:ASRT)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxOcXZrUGZmQUJ1bHJCMjZDS3RuWGVtNU5oQm00TWVRcTlrZ1RqOE43amlYSHo0TVUzZ3RHVkNGNExfLWJOeG5DSTl4RHVvTm5wRmZPNjJiMWhZMWlKRGtncHA1OTNSU3RZbElmb0txQ05ET1NocWwzdXBBYjZjSURvVG41VEkwYkJBZmNScVpKcUlXU083eUN4eXJ2a2JLLXpSYWtaaU04UWhINzRTdUdLVFI4aDBIcE5qOTNuZm5Cc2h4OUFLdWFOTEZLTGxBZm1mOHd3?oc=5","date":"2023-07-31","type":"pipeline","source":"globenewswire.com","summary":"Assertio Holdings, Inc. Closes Spectrum Pharmaceuticals Transaction - globenewswire.com","headline":"Assertio Holdings, Inc. Closes Spectrum Pharmaceuticals Transaction","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxNOHpIV1JkWW50dHZxTEpCLTU5SXp1MEYyTUEyYkdaaWhtYW41eXdUeFpic2pKRmFGREZDSlVwQmllckhXT2hYckpGWTlNanpDT1JETGpSUEZNVGIwS01FZW9BVmxhM2xXT2xlcHZsaFFCVDYtVjM3LXh4Qm95SURPaEVzWUVkQm1vV2h4OEY2UlI2emloWGR4aTgtZFV5LXhad1prY1VLb09vUzZhRW4w?oc=5","date":"2023-04-26","type":"pipeline","source":"Latham & Watkins LLP","summary":"Latham & Watkins Advises Assertio Holdings in Acquisition of Spectrum Pharmaceuticals - Latham & Watkins LLP","headline":"Latham & Watkins Advises Assertio Holdings in Acquisition of Spectrum Pharmaceuticals - Latham & Watkins LLP","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPcDNDaHdxd2JDNllMTW9lMEpiSkU1c1ZVLUg5aWs4UFRjVUxyakIxdU9CY1EyOGluTjZsc3NLcVdtX3VncHhxTUM4UjRJMjhLeklwaVdKYjFKNjdjZ3FHQmozcDNzMVJKMnpqLW9pU1BtTFYyajBIenF2MFIwOFdaVm82NC1rN2otbFE?oc=5","date":"2023-04-25","type":"deal","source":"Yahoo Finance","summary":"Assertio Scoops Up Spectrum Pharma In $248M Stock Deal - Yahoo Finance","headline":"Assertio Scoops Up Spectrum Pharma In $248M Stock Deal","sentiment":"neutral"}],"patents":[{"drugName":"Toviaz","drugSlug":"fesoterodine","patentNumber":"","type":"Patent Cliff","expiryDate":"2025-06-01","territory":"US","annualRevenue":143800000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Mallinckrodt Pharmaceuticals","Endo International","Pacira Pharmaceuticals"],"therapeuticFocus":["Pain Management","Neurology"],"financials":{"source":"sec_edgar+yahoo","revenue":118713000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":118713000,"period":"2025-12-31"},{"value":124961000,"period":"2024-12-31"},{"value":124961000,"period":"2024-12-31"},{"value":152069000,"period":"2023-12-31"},{"value":152069000,"period":"2023-12-31"}],"grossProfit":83330000,"grossProfitHistory":[{"period":"2025-12-31","value":83330000},{"period":"2024-12-31","value":85734000},{"period":"2023-12-31","value":125049000},{"period":"2022-12-31","value":137486000}],"rdSpend":1690000,"rdSpendHistory":[{"period":"2025-12-31","value":1690000},{"period":"2024-12-31","value":3822000},{"period":"2023-12-31","value":2843000},{"period":"2022-12-31","value":0}],"sgaSpend":69000000,"operatingIncome":-17223000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-17223000},{"period":"2024-12-31","value":-18783000},{"period":"2023-12-31","value":16041000},{"period":"2022-12-31","value":58092000}],"netIncome":-30375000,"netIncomeHistory":[{"period":"2025-12-31","value":-30375000},{"period":"2024-12-31","value":-21581000},{"period":"2023-12-31","value":-331942000},{"period":"2022-12-31","value":109625000}],"eps":-0.316,"epsHistory":[{"period":"2025-12-31","value":-0.316},{"period":"2024-12-31","value":-3.45},{"period":"2023-12-31","value":-70.05},{"period":"2022-12-31","value":30.45}],"cash":10229000,"cashHistory":[{"period":"2025-12-31","value":10229000},{"period":"2024-12-31","value":50588000},{"period":"2023-12-31","value":73441000},{"period":"2022-12-31","value":64941000}],"totalAssets":266970000,"totalLiabilities":173018000,"totalDebt":40009000,"equity":93952000,"operatingCashflow":-28182000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-28182000},{"period":"2024-12-31","value":26408000},{"period":"2023-12-31","value":49604000},{"period":"2022-12-31","value":78598000}],"capex":-628000,"capexHistory":[{"period":"2023-12-31","value":-628000},{"period":"2022-12-31","value":-274000},{"period":"2021-12-31","value":-53000}],"freeCashflow":-28182000,"dividendsPaid":null,"buybacks":-189000,"employees":53,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":13135000,"ebit":-11096000,"ebitda":-5257000,"period":"2025-12-31","revenue":13542000,"epsBasic":-1.86,"netIncome":-11927000,"rdExpense":486000,"epsDiluted":-1.86,"grossProfit":10276000,"operatingIncome":-9149000},{"sga":16930000,"ebit":12048000,"ebitda":17678000,"period":"2025-09-30","revenue":49459000,"epsBasic":1.8,"netIncome":11445000,"rdExpense":379000,"epsDiluted":1.65,"grossProfit":35805000,"operatingIncome":12902000},{"sga":16960000,"ebit":-15646000,"ebitda":-6379000,"period":"2025-06-30","revenue":29222000,"epsBasic":-2.55,"netIncome":-16352000,"rdExpense":387000,"epsDiluted":-2.55,"grossProfit":18545000,"operatingIncome":-8035000},{"sga":21975000,"ebit":-12646000,"ebitda":-3377000,"period":"2025-03-31","revenue":26488000,"epsBasic":-2.1,"netIncome":-13541000,"rdExpense":438000,"epsDiluted":-2.1,"grossProfit":18702000,"operatingIncome":-12944000},{"sga":21416000,"ebit":-10099000,"ebitda":-3388000,"period":"2024-12-31","revenue":32183000,"epsBasic":-1.65,"netIncome":-10476000,"rdExpense":1286000,"epsDiluted":-1.65,"grossProfit":20572000,"operatingIncome":-8801000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":23.32,"previousClose":23.32,"fiftyTwoWeekHigh":23.36,"fiftyTwoWeekLow":8.61,"fiftyTwoWeekRange":"8.61 - 23.36","fiftyDayAverage":17.32,"twoHundredDayAverage":13.13,"beta":0.45,"enterpriseValue":121864120,"forwardPE":9,"priceToBook":1.59,"priceToSales":1.27,"enterpriseToRevenue":1.03,"enterpriseToEbitda":9.53,"pegRatio":0,"ebitda":12782000,"ebitdaMargin":10.8,"freeCashflow":-16582250,"operatingCashflow":-28182000,"totalDebt":40253000,"debtToEquity":42.8,"currentRatio":1.7,"returnOnAssets":-3.9,"returnOnEquity":-28.3,"analystRating":"2.5 - Buy","recommendationKey":"buy","numberOfAnalysts":3,"targetMeanPrice":24.43,"targetHighPrice":28,"targetLowPrice":21.8,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":2.1,"institutionHeldPercent":34.1,"sharesOutstanding":6462180,"floatShares":5625788,"sharesShort":287241,"shortRatio":1.16,"shortPercentOfFloat":4.4,"epsTrailing":-5.55,"epsForward":2.59,"revenuePerShare":18.54,"bookValue":14.63,"officers":[{"age":59,"name":"Mr. Mark L.  Reisenauer","title":"CEO & Director"},{"age":54,"name":"Mr. Paul  Schwichtenberg","title":"President & COO"},{"age":41,"name":"Mr. Ajay  Patel","title":"Executive VP & CFO"},{"age":42,"name":"Mr. Sam  Schlessinger","title":"Executive VP & General Counsel"},{"age":null,"name":"Dr. Howard J. Franklin M.B.A., M.D.","title":"Senior Vice President of Medical"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.assertiotx.com","phone":"224 419 7106"}}